EndoRisk®: Predictive genetic companion diagnostic

(in licensed from Juneau Biosciences)

EndoRisk®: Predictive genetic companion diagnostic

· Pending initial launch to fertility clinics
· Pending launch to general primary care provider and OBGYN market
· 27,000,000 symptomatic women in the United States
· Greater than $1Billion US Market
· Today, endometriosis is diagnosed through laparoscopy with costs that exceed $15,000
· In over 50% of cases (today’s “gold standard”) diagnosis is NOT confirmed
· Companion diagnostic for therapeutics
· Initial base patent issued in January 2015 by USPTO
· Additional patent applications pending